Skip to main content

Table 2 Percent of responders in um-PEA TP and TP groups at different follow-up times

From: The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms

Parameters

Goals

Percent of responders in um-PEA TP group/TP group at different follow-up times

T1

T2

T3

VAS

Reduction

      

≥2

3.3

0

90***

16

100***

68

≥3

3.3

0

30**

0

63.3***

8

≥4

0

0

0

0

20*

0

VAS scorea ≤ 3

0

0

0

0

0

0

DN4

Reduction

      

≥1

46. 7**

16

93.3***

36

100.0

96

≥2

6. 7

0

73.3***

4

86. 7***

20

DN4 scoreb < 4

3. 3

0

6. 7

0

76. 7***

0

ODQ

Reduction

      

≥10

86.7**

48

≥15

70.0**

24

≥20

53.3**

16

  1. aPercentage of patients who achieved a VAS score ≤ 3
  2. bPercentage of patients who achieved a DN4 score < 4
  3. *p < 0.05
  4. **p < 0.01
  5. ***p < 0.0001